Terms: = Liver cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H
1236 results:
1. Predicting effect of anti-PD-1/pd-l1 inhibitors therapy for hepatocellular carcinoma by detecting plasma metabolite based on UHPLC-MS.
Liu B; Shi J; Su R; Zheng R; Xing F; Zhang Y; Wang N; Chen H; Feng S
Front Immunol; 2024; 15():1370771. PubMed ID: 38707906
[TBL] [Abstract] [Full Text] [Related]
2. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma.
Li X; Pan YF; Chen YB; Wan QQ; Lin YK; Shang TY; Xu MY; Jiang TY; Pei MM; Tan YX; Dong LW; Wan XY
Cell Death Dis; 2024 Apr; 15(4):300. PubMed ID: 38684648
[TBL] [Abstract] [Full Text] [Related]
3. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.
Du J; Zhang E; Huang Z
Front Immunol; 2024; 15():1358306. PubMed ID: 38665910
[TBL] [Abstract] [Full Text] [Related]
4. The PD-1/pd-l1 Axis in the Biology of MASLD.
Pipitone RM; Lupo G; Zito R; Javed A; Petta S; Pennisi G; Grimaudo S
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612483
[TBL] [Abstract] [Full Text] [Related]
5. The predictive value of pd-l1 expression in response to anti-PD-1/pd-l1 therapy for biliary tract cancer: a systematic review and meta-analysis.
Yoon SB; Woo SM; Chun JW; Kim DU; Kim J; Park JK; So H; Chung MJ; Cho IR; Heo J
Front Immunol; 2024; 15():1321813. PubMed ID: 38605964
[TBL] [Abstract] [Full Text] [Related]
6. Acesulfame potassium upregulates pd-l1 in HCC cells by attenuating autophagic degradation.
Kim DH; Kwon EJ; Park KG; Jin J; Byun JK
Biochem Biophys Res Commun; 2024 Jun; 711():149921. PubMed ID: 38603831
[TBL] [Abstract] [Full Text] [Related]
7. Discovery of Novel Heterotricyclic Compounds as DNA-Dependent Protein Kinase (DNA-PK) Inhibitors with Enhanced Chemosensitivity, Oral Bioavailability, and the Ability to Potentiate cancer Immunotherapy.
Cheng B; Shi Y; Shao C; Wang S; Su Z; Liu J; Zhou Y; Fei X; Pan W; Chen J; Lu Y; Xiao J
J Med Chem; 2024 Apr; 67(8):6253-6267. PubMed ID: 38587857
[TBL] [Abstract] [Full Text] [Related]
8. Case report: Envafolimab causes local skin necrosis.
Liu JJ; Xu XY; Han H; Wang T; Zhang W; Cui J; Semenov M
Front Immunol; 2024; 15():1336311. PubMed ID: 38585260
[TBL] [Abstract] [Full Text] [Related]
9. Identification of molecular characteristics of hepatocellular carcinoma with microvascular invasion based on deep targeted sequencing.
Zheng L; Wang Y; Liu Z; Wang Z; Tao C; Wu A; Li H; Xiao T; Li Z; Rong W
Cancer Med; 2024 Apr; 13(7):e7043. PubMed ID: 38572921
[TBL] [Abstract] [Full Text] [Related]
10. Investigation of the feasibility of NRAV as a biomarker for hepatocellular carcinoma.
Liu J; Li W; Lu R; Xu J; Jiang C; Duan J; Zhang L; Wang G; Chen J
Oncol Res; 2024; 32(4):717-726. PubMed ID: 38560576
[TBL] [Abstract] [Full Text] [Related]
11. The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy.
Zeng Y; Huang J; Pang J; Pan S; Wu Y; Jie Y; Li X; Chong Y
Front Immunol; 2024; 15():1330644. PubMed ID: 38558804
[TBL] [Abstract] [Full Text] [Related]
12. Establishment of a murine hepatocellular carcinoma model by hydrodynamic injection and characterization of the immune tumor microenvironment.
Repáraz D; Casares N; Fuentes A; Navarro F
Methods Cell Biol; 2024; 185():79-97. PubMed ID: 38556453
[TBL] [Abstract] [Full Text] [Related]
13. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
Kim S; Ghiringhelli F; de la Fouchardière C; Evesque L; Smith D; Badet N; Samalin E; Lopez-Trabada Ataz D; Parzy A; Desramé J; Baba Hamed N; Buecher B; Tougeron D; Bouché O; Dahan L; Chibaudel B; El Hajbi F; Mineur L; Dubreuil O; Ben Abdelghani M; Pecout S; Bibeau F; Herfs M; Garcia ML; Meurisse A; Vernerey D; Taïeb J; Borg C
Lancet Oncol; 2024 Apr; 25(4):518-528. PubMed ID: 38547895
[TBL] [Abstract] [Full Text] [Related]
14. An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.
Levy A; Morel D; Texier M; Sun R; Durand-Labrunie J; Rodriguez-Ruiz ME; Racadot S; Supiot S; Magné N; Cyrille S; Louvel G; Massard C; Verlingue L; Bouquet F; Bustillos A; Bouarroudj L; Quevrin C; Clémenson C; Mondini M; Meziani L; Tselikas L; Bahleda R; Hollebecque A; Deutsch E
Mol Cancer; 2024 Mar; 23(1):61. PubMed ID: 38519913
[TBL] [Abstract] [Full Text] [Related]
15. Long non-coding RNAFOXD1-AS1 modulated CTCs epithelial-mesenchymal transition and immune escape in hepatocellular carcinoma in vitro by sponging miR-615-3p.
Guo BL; Zheng QX; Jiang YS; Zhan Y; Huang WJ; Chen ZY
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2050. PubMed ID: 38517478
[TBL] [Abstract] [Full Text] [Related]
16. Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis.
Ernst SM; Hofman MM; van der Horst TE; Paats MS; Heijboer FWJ; Aerts JGJV; Dumoulin DW; Cornelissen R; von der Thüsen JH; de Bruijn P; Hoop EO; Mathijssen RHJ; Koolen SLW; Dingemans AC
EBioMedicine; 2024 Apr; 102():105074. PubMed ID: 38507877
[TBL] [Abstract] [Full Text] [Related]
17. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
18. Fibroblast activation protein promotes progression of hepatocellular carcinoma via regulating the immunity.
Wang X; Niu R; Yang H; Lin Y; Hou H; Yang H
Cell Biol Int; 2024 May; 48(5):577-593. PubMed ID: 38501437
[TBL] [Abstract] [Full Text] [Related]
19. PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in pd-l1-negative metastatic lung adenocarcinoma: a real-world data.
Ge Y; Zhan Y; He J; Li J; Wang J; Wei X; Wang C; Gao A; Sun Y
J Cancer Res Clin Oncol; 2024 Mar; 150(3):135. PubMed ID: 38499838
[TBL] [Abstract] [Full Text] [Related]
20. FASN Inhibition Decreases MHC-I Degradation and Synergizes with pd-l1 Checkpoint Blockade in Hepatocellular Carcinoma.
Huang J; Tsang WY; Fang XN; Zhang Y; Luo J; Gong LQ; Zhang BF; Wong CN; Li ZH; Liu BL; Huang JL; Yang YM; Liu S; Ban LX; Chan YH; Guan XY
Cancer Res; 2024 Mar; 84(6):855-871. PubMed ID: 38486485
[TBL] [Abstract] [Full Text] [Related]
[Next]
